Celltrion's Biosimilar Gets FDA Panel Nod Despite Extrapolation Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee discussion reflects tension between desire for indication-specific efficacy data and recognition of benefits of 351(k) pathway.